Cargando…

Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation

BACKGROUND: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has ravaged lives across the globe since December 2019, and new cases are still on the rise. Peoples’ ongoing sufferings trigger scientists to develop safe and effective remedies to treat this deadly viral disease. While repurposing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bepari, Asim Kumar, Reza, Hasan Mahmud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2021
Materias:	Computational Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051358/ https://www.ncbi.nlm.nih.gov/pubmed/33954055 http://dx.doi.org/10.7717/peerj.11261

Ejemplares similares

Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)

Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL(pro) through high-throughput virtual screening and molecular dynamics simulation
por: Liu, Wen-Shan, et al.
Publicado: (2021)

Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CL(pro) inhibitors
por: Nukoolkarn, Veena, et al.
Publicado: (2008)

COVID-19: Lessons from Norway tragedy must be considered in vaccine rollout planning in least developed/developing countries
por: Bari, Razmin, et al.
Publicado: (2021)

In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023)

Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
por: Kuzikov, Maria, et al.
Publicado: (2021)

Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening
por: Abdusalam, Ashraf Ahmed Ali, et al.
Publicado: (2020)

Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL(pro)
por: Wang, Ruyu, et al.
Publicado: (2021)

Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits
por: Mukherjee, Prasenjit, et al.
Publicado: (2008)

Identification of potential inhibitors of omicron variant of SARS-Cov-2 RBD based virtual screening, MD simulation, and DFT
por: Lü, Xudong, et al.
Publicado: (2022)

Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants
por: Jukič, Marko, et al.
Publicado: (2021)

Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL(pro) Inhibitors
por: Rawson, Jonathan M. O., et al.
Publicado: (2021)

QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CL(pro) Inhibitor: GA-MLR QSAR modeling supported by molecular Docking, molecular dynamics simulation and MMGBSA calculation approaches
por: Jawarkar, R.D., et al.
Publicado: (2022)

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
por: Zhu, Wei, et al.
Publicado: (2020)

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening
por: Zhu, Wei, et al.
Publicado: (2020)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

A Mechanistic Review of β-Carotene, Lutein, and Zeaxanthin in Eye Health and Disease
por: Johra, Fatima Tuj, et al.
Publicado: (2020)

Potential Broad Spectrum Inhibitors of the Coronavirus 3CL(pro): A Virtual Screening and Structure-Based Drug Design Study
por: Berry, Michael, et al.
Publicado: (2015)

Profiling of Substrate Specificity of SARS-CoV 3CL(pro)
por: Chuck, Chi-Pang, et al.
Publicado: (2010)

Discovery of Diverse Natural Products as Inhibitors of SARS-CoV-2 M(pro) Protease through Virtual Screening
por: Rubio-Martínez, Jaime, et al.
Publicado: (2021)

Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design
por: Meyer-Almes, Franz-Josef
Publicado: (2020)

Identification of PARP12 Inhibitors By Virtual Screening and Molecular Dynamics Simulations
por: Almeleebia, Tahani M., et al.
Publicado: (2022)

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors
por: Regnier, Thomas, et al.
Publicado: (2009)

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro)
por: Du, Ruikun, et al.
Publicado: (2021)

Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL(pro) covalent inhibitors
por: Stille, Julia K., et al.
Publicado: (2022)

Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL(pro) and M(pro)/ 3CL(pro): molecular docking and simulation studies of three pertinent medicinal plant natural components
por: Verma, Devvret, et al.
Publicado: (2021)

Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization
por: Mercorelli, Beatrice, et al.
Publicado: (2022)

In search of SARS CoV-2 replication inhibitors: Virtual screening, molecular dynamics simulations and ADMET analysis
por: Nagar, Prinsa R., et al.
Publicado: (2021)

Protocol for production and purification of SARS-CoV-2 3CL(pro)
por: Mazzei, Luca, et al.
Publicado: (2023)

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs
por: Li, Zhe, et al.
Publicado: (2020)

Virtual Reality simulation for the ALPHA experiment
por: Zammit, Dylan
Publicado: (2019)

Virtual Crowds: Methods, Simulation, and Control
por: Pelechano, Nuria, et al.
Publicado: (2008)

Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease
por: Liu, Yu-Chih, et al.
Publicado: (2005)

Identification of natural compounds targeting SARS-CoV-2 Mpro by virtual screening and molecular dynamics simulations
por: Zhang, Chuanming, et al.
Publicado: (2022)

Virtual Screening and Molecular Design of Potential SARS-COV-2 Inhibitors
por: Tinkov, O. V., et al.
Publicado: (2021)

Screening of plasma IL-6 and IL-17 in Bangladeshi lung cancer patients
por: Shill, Manik Chandra, et al.
Publicado: (2023)

A Bioluminescent 3CL(Pro) Activity Assay to Monitor SARS-CoV-2 Replication and Identify Inhibitors
por: Mathieu, Cyrille, et al.
Publicado: (2021)

Identification of vaccine targets & design of vaccine against SARS-CoV-2 coronavirus using computational and deep learning-based approaches
por: Abbasi, Bilal Ahmed, et al.
Publicado: (2022)

Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL(Pro) inhibitors
por: Kumar, Vathan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1vupu5749tdk1jllbu0nlla46o